Biokin Pharmaceutical (688506.SH): Clinical trial of BL-M12D1 for injection (ADC) approved

Zhitong Finance APP News, Baili Tianheng (688506.SH) issued an announcement that the company recently received the "Drug Clinical Trial Approval Notice" officially approved and issued by the National Medical Products Administration (NMPA), and the clinical trial of the company's independently developed innovative biologic drug BL-M12D1 for injection (ADC) has been approved. BL-M12D1 for injection is an ADC drug derived from the same technology platform as iza-bren and sharing the same "linker + toxin" platform with Yizekang (lunconibartin, BL-B01D1/iza-bren), and its indication is relapsed or refractory hematological malignancies.